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Abstract
Skeletal muscle overload induces the expression of angiogenic factors such as vascular endothelial growth factor (VEGF) and
matrix metalloproteinase (MMP)-2, leading to new capillary growth. We found that the overload-induced increase in
angiogenesis, as well as increases in VEGF, MMP-2 and MT1-MMP transcripts were abrogated in muscle VEGF KO mice,
highlighting the critical role of myocyte-derived VEGF in controlling this process. The upstream mediators that contribute to
overload-induced expression of VEGF have yet to be ascertained. We found that muscle overload increased
angiotensinogen expression, a precursor of angiotensin (Ang) II, and that Ang II signaling played an important role in
basal VEGF production in C2C12 cells. Furthermore, matrix-bound VEGF released from myoblasts induced the activation of
endothelial cells, as evidenced by elevated endothelial cell phospho-p38 levels. We also found that exogenous Ang II
elevates VEGF expression, as well as MMP-2 transcript levels in C2C12 myotubes. Interestingly, these responses also were
observed in skeletal muscle endothelial cells in response to Ang II treatment, indicating that these cells also can respond
directly to the stimulus. The involvement of Ang II in muscle overload-induced angiogenesis was assessed. We found that
blockade of AT1R-dependent Ang II signaling using losartan did not attenuate capillary growth. Surprisingly, increased
levels of VEGF protein were detected in overloaded muscle from losartan-treated rats. Similarly, we observed elevated VEGF
production in cultured endothelial cells treated with losartan alone or in combination with Ang II. These studies conclusively
establish the requirement for muscle derived VEGF in overload-induced angiogenesis and highlight a role for Ang II in basal
VEGF production in skeletal muscle. However, while Ang II signaling is activated following overload and plays a role in
muscle VEGF production, inhibition of this pathway is not sufficient to halt overload-induced angiogenesis, indicating that
AT1-independent signals maintain VEGF production in losartan-treated muscle.
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Introduction
Communication between skeletal muscle fibers and the
microcirculation is critical to ensure that the metabolic demands
of the muscle are met. Angiogenesis, the process of blood vessel
growth from pre-existing vessels, is induced in response to
increased muscle activity, through the coordinated actions of
growth factors and matrix degrading enzymes [1–3]. Matrix
metalloproteinase (MMP)-2, which facilitates basement membrane
degradation and capillary sprouting, is elevated in rodent muscle
subjected to overload or electrical stimulation [2,4] and in human
muscle following exercise training [5]. Inhibition of MMP activity
significantly attenuates the angiogenic response to chronic muscle
activity [4]. Vascular endothelial growth factor (VEGF) plays a
critical role in angiogenesis through promotion of endothelial cell
proliferation and migration [6–9], and through regulating the
production of MMPs [10,11]. Reduction of VEGF signaling,
either through competitive blockade of VEGFR activation
(VEGF-TRAP) or by conditional deletion of myocyte VEGF,
prevents capillary growth in response to muscle overload or
exercise training, respectively [12,13].
Recent studies have illustrated that cross-talk between myocytes
and endothelial cells contribute to the regulation of angiogenesis.
In vitro sprouting of microvessels and proliferation of cultured
endothelial cells can be enhanced by co-culture with satellite cells
[14,15], or with conditioned media from satellite cells, a response
which is attenuated when soluble VEGF receptors are added to
the media [14]. VEGF not only promotes angiogenesis, but also is
a regulator of myocyte differentiation and survival [16]. While
diffusion of soluble VEGF originating from muscle cells may serve
to activate endothelial cells, VEGF isoforms 164 and 188 are the
predominant isoforms expressed in adult mouse skeletal muscle
[16], and these isoforms have heparin binding domains that
promote their interaction with the extracellular matrix (ECM)
[17]. Matrix bound VEGF retains bioactivity, and has been shown
to activate the p38 MAPK pathway in endothelial cells [17,18].
Considering the close proximity of myocytes and capillary
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endothelial cells within skeletal muscle, matrix-associated VEGF
may play an important role in crosstalk between the two cell types.
Transcriptional regulation of VEGF by HIF1a and PGC1a/
ERRa is well established to occur under conditions of low oxygen
tension, nutrient stress and in response to repeated bouts of
exercise [19–21]. However, additional mechanisms may contrib-
ute to basal and activity-induced VEGF production within muscle
[22]. Angiotensin II (Ang II) is implicated in both muscle
remodeling and new capillary growth in response to muscle
trauma, electrical stimulation, short-term training or overload
[23–27]. Local production of Ang II within the muscle is likely to
occur, given that myocytes produce all necessary components of
the signaling pathway including angiotensinogen, the renin-like
enzyme cathepsin D, angiotensin converting enzyme (ACE) and
both angiotensin receptors (AT1R and AT2R) [28–30]. Ang II
involvement in crosstalk between cultured myocytes and endothe-
lial cells has been reported to occur by both direct and indirect
signaling mechanisms. Ang II stimulation of endothelial cells
induces network formation, which can be blocked by the AT1R
inhibitor losartan [25]. A similar response is evoked by exposing
endothelial cells to conditioned media from C2C12 myocytes, and
this is attenuated by pre-treatment of C2C12 cells with the ACE
inhibitor captopril [25], suggesting that myocytes release Ang II,
which then exerts angiogenic effects directly on endothelial cells.
Alternatively, Ang II has been reported to induce VEGF
production in retinal pericytes and smooth muscle cells [31,32]
and has been correlated with VEGF release from cardiac myocytes
[33]. Thus, Ang II may promote angiogenesis indirectly by acting
first on skeletal myocytes to induce VEGF production, which in
turn would activate the angiogenic cascade within neighbouring
endothelial cells.
The importance of muscle-derived VEGF to muscle overload-
induced angiogenesis and the contribution of the Ang II signaling
to this process has yet to be fully ascertained. We hypothesized that
muscle-derived VEGF plays a critical role in the angiogenic
response to muscle overload and that the Ang II signaling pathway
is an important upstream mediator of myocyte-endothelial cell
communication and overload-induced capillary growth.
Methods
Ethical Approval
Animal studies were carried out with approval from the York
University Committee on Animal Care and performed in
accordance with the animal care procedures at York University
and the American Physiological Society’s guiding principles in the
care and use of animals.
Materials
Chemicals, including Ang II, were purchased from Sigma-
Aldrich Canada (Oakville, Ontario) and losartan was obtained
from LKT Laboratories (St. Paul, MN), while the VEGFR2
inhibitor SU4312 was purchased from Santa Cruz Biotechnologies
(Santa Cruz, CA) and the AT2R agonist (CGP42112) and
antagonist (PD123319) were purchased from Cedarlane Labora-
tories (Mississauga, ON).
Animal Studies
Mice. Muscle VEGF KO mice (VEGFLoxP mice on a C57Bl/
6 background crossbred with Myo-Cre mice expressing cre
recombinase under the control of the muscle creatine kinase
promoter) [12,34] and littermate controls (VEGFLoxP) were bred
and genotyped at the West Virginia animal facility and then
transferred to the animal facility at York University. Mean age of
the mice at the time of experiment was 66+/23 days (VEGFLoxP)
and 70+/23 days (Myo-Cre:VEGFLoxP). Overload of the extensor
digitorum longus (EDL) muscle was induced through unilateral
extirpation of the tibialis anterior (TA) muscle [3], while animals
were under isoflurane anesthesia. Sham surgeries consisted of TA
exposure without its removal, followed by suturing of the overlying
skin. WT (VEGFLoxP) and KO (Myo-Cre:VEGFLoxP) animals were
divided into 4 groups: 7 day Sham (n= 4 for WT and KO), 7 day
OL (n= 3 for WT and n= 4 for KO), 14 day Sham (n= 10 for WT
and n= 4 for KO) and 14 day OL (n= 7 for WT and n= 5 for
KO). After 7 or 14 days, animals were anaesthetized with
isoflurane and the EDL muscle was removed for further analysis.
C57BL/6 mice were used to assess angiotensinogen levels. Sham
and overload surgeries were performed as described above.
Animals were divided into 2 groups sham (n= 3) and overload
(n= 6). After 5 days, animals were anesthetized with isoflurane and
the EDL muscle was removed for further analysis.
Rats. Male Sprague-Dawley rats (approximately 375 g at
sacrifice; Charles River Laboratories, Quebec, Canada) were used
to test the effect of AT1R blockade on overload-induced
angiogenesis. Sham and overload surgeries were performed as
described for mice. Rats were divided into 4 groups; sham +
vehicle (n = 4), overload + vehicle (n = 4), sham + Losartan (n= 4)
and overload + Losartan (n= 4). Losartan (20 mg/kg/day) was
delivered in the drinking water [35–38]. Treatment began 4 days
in advance of the overload surgery, and continued throughout the
duration of the experiment. After 14 days, all rats were
anaesthetized (i.p. injection of 80 mg/kg ketamine and 10 mg/
kg xylazine) and the EDL muscle was removed for further analysis.
Capillary Number
Capillary to muscle fiber ratio was assessed as an indicator of
angiogenesis. 10 mm cross-sections of frozen mouse or rat EDL
muscle were fixed in cold acetone and stained with FITC-
conjugated Griffonia simplicifolia I isolectin (1:100; Vector Labs)
for 30 minutes. Sections were viewed on an Olympus microscope
(x20 objective). Capillary and muscle fiber counts were averaged
from 10 independent fields of view per rat and 5 independent
fields of view per mouse.
Cell Culture
Primary rat microvascular endothelial cells were isolated from
the EDL and TA muscles, as previously described [39] and the
C2C12 cells were a kind gift from Dr. David Hood, York
University. Both cell lines were cultured under conditions of 37uC
and 6% CO2 on 1.5% gelatin coated flasks with Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum, 1 mM sodium pyruvate, 200 mM L-glutamine, 50
units of penicillin and 0.5 mg/ml streptomycin. In some exper-
iments, C2C12 myoblasts were differentiated to myotubes in
DMEM supplemented with 2% horse serum for 5–8 days.
Endothelial cells or C2C12 myotubes were stimulated with Ang
II (0.1 mM or 1 mM) or treated with the AT1R inhibitor losartan
(0.1 and 1 mM) for the indicated duration. In some experiments,
endothelial cells were treated with the AT2R agonist CGP42112
(100 nM) or the AT2R antagonist PD123319 (1 mM) for 24 hours.
Preparation of C2C12 Cell-Free Matrix
Myoblasts were cultured to confluency on type I collagen-
coated 60 mm dishes. Cells were removed from the type I collagen
coated culture dishes first by incubation with 2 M urea in DMEM
(10 min at 37uC), followed by PBS washes and a 3 minute
incubation with extraction buffer containing 0.5% Triton X-100
and 20 mM ammonium hydroxide [40]. Matrix proteins were
Angiotensin II Regulates VEGF in Skeletal Muscle
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washed extensively with 1X PBS prior to utilization for Western
blotting or in matrix-endothelial cell experiments.
Matrix Experiments
C2C12 myoblasts were plated on type I collagen and cultured to
confluence (48 hours), then incubated overnight in Optimem or
Optimem containing the AT1R inhibitor losartan (0.1 mM).
Endothelial cells were plated on a type I collagen-coated coverslip
and incubated overnight in either media alone or media
containing the VEGFR inhibitor SU4312 (4 mM). Following
removal of C2C12 cells to generate a cell-free matrix (as described
earlier), endothelial cell coverslips were overlaid on the cell cleared
matrix for 5 minutes (cell side in contact with matrix), followed by
protein lysis.
Protein Extraction
Muscle. Frozen tissue was ground to powder and protein was
isolated through brief homogenization in buffer containing
120 mM Tris HCl, 5% glycerol and protease inhibitor cocktail
(Roche). After homogenization, Triton X-100 (Sigma) was added
to a final concentration of 0.1%, as described previously [4].
Endothelial and myotube cell lysates. Cells were lysed in
120 mM Tris HCl, 0.1% Triton X-100 and 5% glycerol or in
RIPA buffer supplemented with 0.1% EDTA-free protease
inhibitor cocktail (P-8340, Sigma), 2 mM sodium orthovanadate,
1 mM sodium fluoride and 1 mM PMSF. The protein concen-
tration of all lysates was determined using the bicinchonic acid
assay (Pierce).
Matrix proteins – After preparation of cell-free matrix, matrix
bound proteins were lysed directly in 1X Laemmli sample buffer
(38 mM Tris, 65 mM DTT, 4% SDS, 5% glycerol).
Western Blotting
Protein samples were prepared under denaturing conditions
and separated on a polyacrylamide gel. Proteins were transferred
to a PVDF membrane (Millipore) and incubated in either 5% milk
or 5% BSA. Membranes were probed for angiotensinogen
(1:1000, Ab108334 Abcam, Toronto, ON), AT1R (1:200, sc-
1173 Santa Cruz), AT2R (1:2000, sc-7420 Santa Cruz), VEGF
(1:200, sc-152 Santa Cruz or 1:200, sc-57496 Santa Cruz),
phospho Ser473-Akt (1:1000, #4051 Cell Signaling; NEB
Canada, Whitby, ON), total Akt (1:1000, #9272 Cell Signaling),
p-p42/p44 (1:1000, #9101 Cell Signaling), p-p38 (1:1000, #9211
Cell Signaling), ß-actin (1:1000, #4967 Cell Signaling) or a/ß
tubulin (1:1000, #2148 Cell Signaling) overnight at 4uC.
Membranes were incubated with anti-rabbit (GE Biosciences;
Baie d’Urfe, Quebec, or Pierce; Fisher Scientific, Whitby ON) or
anti-mouse (Dako; Cedarlane, Burlington, Ontario) HRP second-
ary antibodies. Bound antibodies were detected using Super West
Pico (Pierce; Fisher Scientific, Whitby ON) or Immobilon
(Millipore; Fisher Scientific, Whitby ON) ECL and were visualized
using a digital imaging system (Kodak MM4000Pro) or imaged on
autoradiography film (Hyperfilm, GE Biosciences). Bands were
quantified using Fluorchem (AlphaInnotech) or Carestream
(Kodak) software.
RNA Extraction and qPCR
EDL muscle was lysed using a Retsch MM400 tissue lyser
(GmbH, Haan, Germany) and RNA was isolated using the
RNeasy Fibrous Tissue Mini Kit (Qiagen), using manufacturer’s
instructions. Cultured cells were lysed using cells-to-cDNA II
reagent (Ambion) according to manufacturer’s instructions,
followed by DNase treatment. RNA was reverse transcribed using
M-MuLV reverse transcriptase (NEB Canada). cDNA samples
were analyzed by real time PCR using Universal Fast-PCR mix or
Universal PCR mix (Applied Biosystems) and Taqman probe/
primer sets (Applied Biosystems - Rat: GAPDH -
Rn99999916_S1, VEGF - Rn00582935_m1 and MMP-2 -
Rn02532334_s1. Mouse: MT1-MMP - Mm00485054_m1,
GAPDH - Mm03302249_g1, VEGF - Mm00437306_m1,
MMP-2 Mm00439498_m1, Angiotensinogen -
Mm00599662_m1, Angiotensin type 1a receptor -
Mm01957722_s1, HPRT1 -Mm00446968_m1 ). Real time PCR
was performed using an ABI Prism 7700 Sequence Detector
(Perkin Elmer) and results were analyzed using associated software.
The threshold cycle (Ct) was determined and normalization was
carried out using the comparative Ct method, with GAPDH as the
housekeeping gene, as previously described [41]. The average Ct
for all samples was used as the comparator, which was set to 1.
RT-PCR Screen of VEGF Isoforms
Endothelial cells and C2C12 myotubes were lysed using cells to
cDNA reagent (Ambion) without DNase treatment. PCR condi-
tions were 98uC for 30 seconds followed by 30 cycles of 98uC for
10 seconds, 68uC for 30 seconds and 72uC for 60 seconds followed
by incubation at 72uC for 5 minutes. Primers were designed using
the rat VEGF sequence (Accession # NM_031836.2) with the
forward primer located in exon 4, 59-GAGATGAGCTTCCTA-
CAGGAC-39 and the reverse primer located in exon 9, 59-
GGTGACATGGTTAATCGGTCTTTC-39. The expected
product sizes were 171 bp for VEGF120, 300 bp for VEGF164,
and 372 bp for VEGF188.
Statistics
Data are presented as mean 6 SEM. Comparisons between
groups were performed using Student’s t-test, one or two way
ANOVA followed by Tukey’s or Bonferroni’s multiple comparison
tests with GraphPad Prism 4. Statistical significance was set at
p,0.05.
Results
Loss of Myocyte VEGF Prevents Overload-induced
Angiogenesis
Overload of the extensor digitorum longus (EDL) results in
significantly enhanced production of pro-angiogenic factors after
4–7 days, and detectable increases in capillary number after 14
days [1,2,41,42]. Previously, skeletal muscle deletion of VEGF was
shown to significantly reduce basal capillary number in skeletal
muscle and to impair the exercise-induced angiogenesis response
[12,34]. To assess the importance of muscle VEGF to overload-
induced angiogenesis, we examined mRNA levels of pro-
angiogenic factors VEGF, MMP-2 and MT1-MMP after 7, and
capillary growth after 14, days of EDL overload in wildtype or
muscle VEGF-deficient mice.
14 days of EDL muscle overload significantly increased the
capillary-to-muscle fiber ratio in wild-type mice (Figure 1A, B) and
this response was abolished in muscle VEGF knockout mice
(Figure 1A, B). We observed the expected increase in VEGF
mRNA [42] following overload in wild-type animals, while muscle
VEGF-deficient mice exhibited no VEGF response to the overload
stimulus (Figure 1C). Consistent with previous observations in rats
[2,41], muscle overload significantly increased both MMP-2 and
MT1-MMP mRNA expression in wild-type animals (Figure 1D,
E). Previously, we reported that VEGF induces the expression of
these proteases in endothelial cells [10,11]. In agreement with
those findings, we observed that the MMP-2 and MT1-MMP
Angiotensin II Regulates VEGF in Skeletal Muscle
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mRNA responses to muscle overload were attenuated significantly
in muscle VEGF-deficient mice (Figure 1D, E).
Effect of Skeletal Muscle Overload on Angiotensinogen
Expression
Skeletal muscle is reported to produce components of the renin-
angiotensin system, which can lead to the local production of Ang
II [28,29]. Increased production of angiotensinogen has been
observed in response to muscle stretch in both proliferating and
differentiated C2C12 cells [28]. As those experiments were carried
out in culture, we assessed whether components of the renin-
angiotensin system were modified in response to skeletal muscle
overload in the mouse. We examined mRNA levels of angioten-
sinogen and the AT1a receptor in EDL that was overloaded for 5
days. We observed a significant increase in angiotensinogen
mRNA levels in whole muscle homogenates (Figure 2A), indicat-
ing that it is responsive to muscle overload. However, AT1aR
levels (Figure 2B) were unchanged in response to muscle overload.
Similar to the mRNA levels, overloaded muscle expressed a higher
level of angiotensinogen protein in comparison to sham muscle
(Figure 2C). Conversely, protein levels of both AT1R and AT2R
were detectable but not altered by muscle overload (Figure 2D,E).
VEGF-matrix Interactions Contribute to Endothelial Cell
and Muscle Signaling
Next, we examined whether endogenous Ang II signaling plays
a role in the basal production of VEGF in C2C12 myotubes.
Angiotensinogen was produced by C2C12 cells under resting
conditions, but not detectable in cultured endothelial cells
(Figure 3A). C2C12 cells also predominantly expressed the
AT1R, while AT2R expression was minimally detectable. As
Ang II modulation of VEGF expression in cardiac endothelial cells
occurred via the AT1 receptor [43], we treated cells overnight
with the AT1 receptor inhibitor losartan. Losartan treatment (0.1
and 1.0 mM) significantly reduced basal VEGF mRNA expression
in C2C12 myotubes (Figure 3B). The predominant VEGF
isoforms that are reported to be produced within skeletal muscle
[16] have high affinity for heparin sulphate moieties within matrix
proteins, and as such, are likely to be immobilized by matrix rather
than freely diffusible within the interstitial fluid. We assessed the
VEGF isoforms produced by C2C12 myotubes and compared
them to the isoforms produced by cultured endothelial cells, using
RT-PCR. VEGF isoforms 120 and 164 were detectable within
both cultured C2C12 myotubes and skeletal muscle endothelial
cells (Figure 3C). However, the relative levels of VEGF164
compared to VEGF120 were significantly higher in myotubes
compared to endothelial cells (Figure 3C). VEGF188 was
undetectable in endothelial cells, and was observed infrequently
in C2C12 myocytes.
To detect the matrix-bound fraction of VEGF, myoblasts were
cultured on type I collagen overnight, then cells were removed to
enable analysis of the cell-free matrix-associated proteins. Western
blotting of matrix deposited by unstimulated C2C12 cells revealed
minimal VEGF (21 kDa) within the cell lysate, and substantial
levels of VEGF (27 kDa) associated with the matrix (Figure 3D).
Lack of tubulin immune-reactivity indicated that cellular compo-
Figure 1. Muscle overload-induced angiogenesis is attenuated in muscle VEGF KO animals. Representative inverted grey-scale images of
iso-lectin staining (A) were used to calculate the capillary to muscle fiber ratio (n = 10 for WT Sham, n = 4 for KO Sham, n = 7 for WT OL and n=5 for
KO OL) (B). Muscle subjected to overload for 7 days was lysed for qPCR analysis of VEGF (C), MMP-2 (D) and MT1-MMP (E) transcript levels (n = 4 for WT
Sham, KO Sham and KO OL and n= 3 for WT OL). Values are presented as mean 6 SEM. There was a significant main effect of overload on the
capillary to fiber ratio as well as VEGF, MMP-2 and MT1-MMP transcript levels, as assessed by two way ANOVA (*). Bonferroni’s multiple comparison
posthoc tests revealed a significant difference between the capillary to fiber ratio of KO sham animals compared WT sham animals (**) and a
significant difference in the capillary to fiber ratio and VEGF, MMP-2 and MT1-MMP transcript levels in KO overload animals compared to WT overload
animals (#). WT – wildtype, KO – knockout and OL – overload.
doi:10.1371/journal.pone.0085537.g001
Angiotensin II Regulates VEGF in Skeletal Muscle
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nents did not contribute to the VEGF signal observed in matrix
lysates (Figure 3D). These results demonstrate that, under basal
conditions, skeletal muscle myocytes actively produce VEGF that
is able to bind and accumulate within the underlying matrix.
Finally, we assessed the bioactivity of the matrix-associated VEGF
and whether Ang II signaling played a role in the secretion of
matrix binding variants of VEGF. Activation of the VEGFR2 in
endothelial cells is known to cause the phosphorylation of p38
MAPK [18,44]. Thus, we analyzed endothelial cell phosphoryla-
tion of p38 MAPK (p-p38) as an indicator of VEGFR2 activation.
Direct contact of endothelial cells with the cell-free C2C12 matrix
resulted in an increase in p38 phosphorylation, as compared to
endothelial cells incubated on type I collagen matrix that had not
been exposed previously to C2C12 cells (Figure 3E). These results
indicate that matrix bound VEGF deposited by C2C12 cells is
able to activate endothelial cells. Incubation of endothelial cells on
matrix derived from C2C12 cells that had been pre-treated with
losartan resulted in decreased p-p38 levels as did pre-treatment of
the endothelial cells with an inhibitor of the VEGFR2 (Figure 3E).
Thus, deposition of matrix-associated VEGF by C2C12 cells is
sensitive to AT1R inhibition and the induction of p38 phosphor-
ylation in endothelial cells occurs via the VEGFR2.
Effect of Ang II on VEGF Expression in Skeletal Myocytes
and in Microvascular Endothelial Cells
The above results suggest that endogenous Ang II contributes to
VEGF production by skeletal myocytes. To extend these findings,
we treated C2C12 myotubes with exogenous Ang II. Ang II
treatment (0.1 mM) stimulated a significant increase in VEGF
mRNA (Figure 4A) and protein expression (Figure 4B), as well as
an increase in MMP-2 transcript levels (Figure 4C) in C2C12
myotubes. Ang II (1 mM) induced the phosphorylation of ERK1/2
after 10 minutes, with levels returning to those observed in control
cells by 30 minutes (Figure 4D). Akt phosphorylation was not
affected by Ang II treatment (Figure 4E).
Given that endothelial cells also expressed AT1R and AT2R
(Figure 3A), we also assessed the direct effects of exogenous Ang II
on the same factors within cultured primary microvascular
endothelial cells. Stimulation of microvascular endothelial cells
with Ang II (0.1 mM) resulted in a significant increase in VEGF
mRNA expression after 2 hours (Figure 5A), with protein levels
elevated following overnight Ang II treatment (Figure 5B). MMP-
2 mRNA also was increased significantly by Ang II stimulation
(Figure 5C). Similar to the response observed in C2C12 cells, Ang
II (1 mM) induced the transient phosphorylation of ERK1/2
(Figure 5D) but did not alter Akt phosphorylation (Figure 5E) in
endothelial cells, suggesting the involvement of ERK1/2 in
mediating Ang II signaling.
Role of Ang II in the Angiogenic Response to Muscle
Overload
Based on our observations that VEGF released from skeletal
muscle is critical to overload-induced angiogenesis (Figure 1A, B),
the Ang II signaling pathway is activated in muscle subjected to
overload (Figure 2A) and that Ang II contributes to basal VEGF
production in myocytes (Figure 3A), we hypothesized that AT1R
inhibition would reduce muscle VEGF levels and impair the
angiogenic response to muscle overload. Animals were treated
daily with the AT1R inhibitor losartan (provided in the drinking
water), beginning 4 days prior to the induction of overload.
Losartan treatment did not attenuate the overload-induced
increase in capillary to muscle fiber ratio (Figure 6A, B). In line
Figure 2. Effect of skeletal muscle overload on angiotensinogen and AT receptor expression in skeletal muscle. Muscle subjected to
overload for 5 days was lysed for qPCR analysis of angiotensinogen (A) and AT1aR (B) transcript levels. Protein levels of Angiotensinogen (C), AT1R (D)
and AT2R (E) were assessed by Western Blotting. In each graph, values are presented as mean 6 SEM (n= 3 for Sham and n= 6 for Overload).
Student’s t-test (*) revealed a significant difference between angiotensinogen transcript and protein levels in overload compared to sham animals. OL
– overload, Ang – angiotensinogen, AT1R – Ang II type 1 receptor and AT2R – Ang II type II receptor.
doi:10.1371/journal.pone.0085537.g002
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with a previous study in mice [45], VEGF protein expression in
whole muscle homogenates was elevated following 7 days of
muscle overload (Figure 6C). However, there was a significant
effect of the losartan treatment alone on basal VEGF expression
and the combination of overload and losartan further increased
VEGF expression levels compared with losartan treatment alone,
indicating a possible additive effect of the two treatments.
To elucidate the apparent discrepancy between in vitro and
in vivo findings, we examined the effects of AT1R signaling
inhibition on cultured microvascular endothelial cells. Treatment
of endothelial cells with 0.1 mM losartan had no effect on basal
VEGF expression, while 1.0 mM losartan significantly elevated
endothelial cell VEGF expression (Figure 6D). The increased
VEGF expression in endothelial cells treated with losartan was
unexpected, so we assessed the combined effect of Ang II and
losartan treatment in endothelial cells. VEGF mRNA levels were
increased significantly in endothelial cells treated with both Ang II
and losartan compared to endothelial cells treated with Ang II
Figure 3. Contribution of endogenous Ang II to muscle VEGF production and endothelial cell-muscle cell crosstalk. C2C12 myotubes
and confluent cultures of microvascular endothelial cells were lysed, and endogenous basal levels of angiotensinogen, AT1R and AT2R were assessed
by Western blot analysis (A). In all blots, two independent cultures are shown for each cell type. C2C12 myotubes (n = 3 per condition) were treated
overnight with the AT1R inhibitor Losartan (0.1 mM or 1 mM) and VEGF transcript levels were assessed by qPCR (B). Representative image and the
quantification of RT-PCR analysis of VEGFA isoform expression (VEGF120 ,170 bp; VEGF164 ,300 bp and VEGF180 = not detected) in C2C12 myotubes
and skeletal muscle endothelial cells (C). Two independent samples are shown for both C2C12 and endothelial cells (n = 6 for C2C12 and n= 13 for
endothelial cells). Lysates of matrix bound proteins were assessed for VEGF and tubulin protein expression by Western blotting (D). Cell extract (Ex)
was used as a comparator with extracts of matrix (M) alone. Three independent samples of matrix-associated protein extracts are shown. Tubulin was
detectable within cell extract, but not in matrix-derived extracts. In (E), endothelial cells alone or previously treated with an inhibitor of the VEGFR2,
were incubated on matrix which previously contained C2C12 myoblasts with or without losartan treatment. Representative image and quantification
of phosphorylated p38 levels (n = 6 for E and E+M, n= 5 for E+ML and n= 4 for EV+M). Values are presented as mean 6 SEM. One way ANOVA
followed by Tukey’s multiple comparison test and student’s t-test were used to assess statistical significance which was set as p,0.05. In panel B,
*denotes p,0.05 vs. untreated cells. In panel C, *denotes p,0.05 vs. C2C12 cells and in panel E, *denotes p,0.05 vs. endothelial cells. E – endothelial
cell, Ex - cell extract, Coll- type I collagen matrix, M - matrix lysate, E+M – endothelial cells + matrix from untreated C2C12, E+ML – endothelial cells +
matrix from losartan-treated C2C12 cells and EV+M – endothelial cells pretreated with a VEGFR2 inhibitor + matrix from untreated C2C12.
doi:10.1371/journal.pone.0085537.g003
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alone (Figure 6E). These results reveal that inhibition of AT1R
signaling contributed a stimulatory, rather than inhibitory, effect
on Ang II-induced VEGF mRNA levels in endothelial cells. This
influence did not appear attributable to the actions of the AT2R,
as treatment of endothelial cells with the AT2R agonist CGP
42112 failed to induce an influence on VEGF mRNA levels
(1.060 vs. 0.9360.1; p = 0.5, n= 6), and treatment with an AT2R
antagonist (PD123319) did not prevent the losartan-induced effect
on VEGF mRNA (2.960.4 vs. 3.160.7; p = .8, n = 6).
Discussion
We provided conclusive evidence that muscle-derived VEGF is
an absolute requirement for overload-induced skeletal muscle
angiogenesis. We also established that angiotensinogen mRNA is
elevated following muscle overload and that endogenous Ang II
regulates basal production of VEGF in cultured myocytes. Despite
our finding that exogenous treatment of both myotubes and
endothelial cells with Ang II increased levels of both VEGF and
MMP-2 mRNA expression, we found that inhibition of the AT1R
in vivo does not impair the overload-induced increase in VEGF
expression and new capillary growth.
Studies utilizing mice with deficiency of VEGF in skeletal
muscle have provided evidence that muscle-derived VEGF is a
critical regulator of basal muscle capillarity as well as exercise-
induced angiogenesis [12,34]. Consistent with these reports, we
did not detect capillary growth within overloaded muscle of mice
with myocyte-specific VEGF deficiency. As expected, VEGF
mRNA levels were substantially reduced within muscle extracts of
VEGF knockout mice. Multiple cell types within the skeletal
muscle, including endothelial cells, pericytes and satellite cells as
well as skeletal myocytes, are potential sources of overload-induced
VEGF. However, the complete lack of an increase in VEGF
mRNA within the overloaded VEGF-deficient muscles indicates
that myocytes constitute the key cellular source of VEGF in
response to muscle overload. Abluminal sprouting of endothelial
cells to generate new capillaries requires endothelial cell migration
Figure 4. Effect of Ang II stimulation on VEGF and MMP-2 expression in C2C12 myotubes. C2C12 myoblasts were differentiated in 2%
serum media for 5–8 days until myotubes had formed. Following myotube formation, cells were switched to Opti-mem reduced serum media and
stimulated with Ang II. VEGF mRNA levels were determined by qPCR in response to Ang II (0.1 mM) stimulation for 2 hours (n = 7 per condition) (A).
Representative blot and quantification of VEGF protein expression after overnight stimulation with Ang II (0.1 mM) and normalized to tubulin
(n = 7 per condition) (B). MMP-2 mRNA levels were assessed in response to 2 hour Ang II (0.1 mM) treatment by qPCR (n = 6 per condition) (C). C2C12
myoblasts were stimuated for either 10 or 30 minutes with 1 mM Ang II and then lysed for protein analysis. P-ERK1/2 (n = 3 per condition) (D) and P-
Akt (n = 5 per condition) (E) levels were assessed by Western blotting with activated levels normalized to ß-actin and total Akt levels respectively.
Values are presented as mean 6 SEM. Student’s t-test and one way ANOVA followed by Bonferroni’s multiple comparison test were used to assess
statistical significance which was set as p,0.05. In panels A–D, *denotes p,0.05 vs. untreated cells. C – Control, 10–10 minutes and 30–30 minutes.
doi:10.1371/journal.pone.0085537.g004
Angiotensin II Regulates VEGF in Skeletal Muscle
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e85537
into the surrounding matrix, which is facilitated by the increased
production of matrix-degrading enzymes MMP-2 and MT1-MMP
[2,4]. Consistent with in vitro observations in which VEGF
enhances endothelial cell production of these enzymes [10,11],
we determined that muscle overload fails to enhance MMP-2 and
MT1-MMP transcript levels in muscle VEGF-deficient mice. This
supports the idea that VEGF acts to activate MMPs and that
myocyte-derived VEGF is essential for angio-adaptation. Impor-
tantly, these data further suggest that other paracrine sources of
VEGF are not capable of acting in place of, or rescuing, the loss of
myocyte-derived VEGF.
The renin-angiotensin system has been implicated in adapta-
tions following exposure of cells to mechanical forces. We found
that C2C12, but not cultured endothelial cells, expressed
angiotensinogen protein. In vitro, stretch of both proliferating and
differentiated C2C12 cells elevated angiotensinogen and AT1R
transcript levels [28] and in vivo studies examining the heart
following pressure overload show elevated angiotensinogen, ACE
and AT1R transcript levels [46–48]. Our results presented in this
study reveal novel evidence that the Ang II signaling pathway may
be activated in overloaded skeletal muscle, as observed by elevated
angiotensinogen transcript and protein levels, and therefore may
play a role in the adaptations that occur in the skeletal muscle
micro-environment following overload.
Given the central role established for VEGF in overload-
induced angiogenesis, we have extended the investigation on the
role of myocyte-derived VEGF in modulating endothelial cell
signaling using in vitro experiments on matrix bound VEGF
secreted from C2C12 myoblasts. Here, we demonstrate that
myocyte secretion of VEGF results in accumulation of matrix-
associated VEGF that is capable of activating endothelial cells
(Figure 3). While previous studies have activated endothelial cells
using matrix–associated VEGF [18], this is the first direct evidence
to our knowledge that myocyte-derived VEGF acts in this way.
The deposition of matrix-associated VEGF may create a
chemotactic gradient that provides guidance cues for the tip cells
of nascent capillary sprouts [49,50]. As well, MMPs can cleave the
heparin sulfate binding domain contained within VEGF165 and
VEGF189, releasing a soluble form of VEGF [51]. The increased
production and activation of MMPs that occurs in response to
Figure 5. Effect of Ang II stimulation on VEGF and MMP-2 expression in skeletal muscle endothelial cells. Skeletal muscle endothelial
cells were stimulated for 2 hours with Ang II (0.1 mM) and lysed for qPCR analysis of VEGF (A) and MMP-2 (C) transcript levels (n = 6 per condition). In
(B), endothelial cells were treated overnight with Ang II (0.1 mM) and Western blotting was performed to assess VEGF protein levels, which were
normalized to tubulin (n = 3 per condition). Endothelial cells were stimulated for either 10 or 30 minutes with 1 mM Ang II and then lysed for protein
analysis. P-ERK1/2 (D) and P-Akt (E) levels were assessed by Western blotting and normalized to ß-actin and total Akt levels respectively (n = 3 per
condition). Values are presented as mean 6 SEM. One way ANOVA followed by Tukey’s multiple comparison test and student’s t-test were used to
assess statistical significance (p,0.05). In panels A–D, *denotes p,0.05 vs. untreated cells. C – Control, 10–10 minutes and 30–30 minutes.
doi:10.1371/journal.pone.0085537.g005
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muscle activity or overload [2,4,5,52] would facilitate a rapid
increase in diffusible VEGF within the interstitial fluid, which
could further activate neighbouring satellite cells and endothelial
cells.
Several lines of evidence support a role for Ang II in regulating
VEGF levels, and thus, contributing to capillary homeostasis
within skeletal muscle. We observed that exogenous Ang II
treatment increased VEGF expression in myotubes. These cells
expressed the AT1R, and we found that AT1R blockade by
losartan attenuated the basal production of VEGF by myotubes.
These novel results reveal the importance of Ang II signaling to
basal production of VEGF in myocytes. Furthermore, exogenous
Ang II stimulation of skeletal muscle endothelial cells increased
cellular levels of VEGF mRNA and protein as well as MMP-
2 mRNA. These findings indicate that microvascular endothelial
cells are directly responsive to Ang II stimulation, confirming
previous reports in resistance arteries and retinal and cardiac
microvascular endothelial cells [43,53–55].
Previous studies have demonstrated a role for Ang II in skeletal
muscle angiogenesis (ie. in response to exercise, electrical
stimulation, muscle injury and hindlimb ischemia) [23–25,56], so
our observation that AT1R blockade did not affect overload-
induced angiogenesis was unexpected. Our data suggest that
inhibition of AT1R signaling is not sufficient to reduce overall
VEGF levels within the intact muscle. Animals subjected to both
overload and losartan treatment had an even greater increase in
VEGF expression when compared with animals treated with
losartan alone, indicating that overload and losartan may act
through independent pathways to raise VEGF expression in the
muscle. Notably, losartan treatment alone increased VEGF
mRNA in cultured endothelial cells, opposite to the response seen
in myotubes, and the levels of VEGF in cells treated with Ang II
and losartan were elevated when compared to VEGF levels
following Ang II treatment alone. These data indicate that losartan
increases endothelial cell production of VEGF, which may be a
possible mechanism through which elevated levels of VEGF
protein are maintained in losartan-treated rats.
While the majority of studies indicate that the AT1R mediates
the Ang II-induced increases in VEGF mRNA and protein [43]
and neovascularization [57,58], a role for the AT2R in the
regulation of VEGF production also has been described [59,60].
Endothelial cells express the AT2R subtype [61] and it is feasible
that losartan treatment enhanced VEGF production via enhanced
signaling through the AT2R. Conflicting data on the effects of
Figure 6. Overload-induced angiogenesis is not altered by losartan treatment. Representative inverted grey scale images of iso-lectin
staining (A) were used to calculate capillary to muscle fiber ratio (n = 4 per condition) (B). In (C), VEGF protein levels were assessed by Western
blotting with expression normalized to ß-actin (n = 3 for sham + vehicle, n = 4 for overload + vehicle, overload + losartan, and for sham + losartan).
Skeletal muscle endothelial cells (n = 4 per condition) (D) were treated overnight with the AT1R inhibitor Losartan (0.1 or 1 mM) and in (E) cells were
treated with Ang II (0.1 mM) or Ang II and losartan (1 mM) overnight. Cells were lysed for qPCR analysis of VEGF mRNA levels. Values are presented as
mean 6 SEM. There was a significant main effect of overload on capillary to muscle fiber ratio (*), as assessed by two way ANOVA. For VEGF protein
levels, two way ANOVA revealed a significant main effect of overload (*) and the losartan treatment (**) as well as a significant difference between
overload and overload + losartan conditions and the losartan and overload + losartan conditions (#) by Bonferroni’s multiple comparison test. In (D),
*denotes p,0.05 vs. untreated cells and in E, *denotes p,0.05 vs. Ang II treatment alone. S-sham, O-overload and L-losartan.
doi:10.1371/journal.pone.0085537.g006
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AT2R activation have been reported. On one hand, AT2R
activation on endothelial cells is reported to reduce VEGF-
dependent angiogenesis through inhibition of RhoA GTPase and
cellular migration [61,62]. However, several studies have provided
evidence for a positive role of the AT2R in tumor angiogenesis
[63] and in angiogenic sprouting in the hypoxic heart [64]. Thus,
we considered it possible that Ang II signaling via the AT2R may
play a role in maintaining VEGF production and the angiogenic
response to muscle overload in the presence of AT1R inhibition.
While we did find detectable levels of the AT2R in microvascular
endothelial cells, an AT2R agonist did not influence VEGF
mRNA levels. Furthermore, inhibition of the AT2R using
PD123319 failed to reduce the losartan-induced increase in
VEGF mRNA. Consequently, our data do not support a role for
the activation of an AT2R-dependent response in the presence of
losartan. The mechanism underlying the stimulatory influence of
losartan treatment on the endothelial cells requires further
investigation.
Alternatively, the sustained levels of VEGF in the overloaded
muscle may be seen as evidence for redundancy in the pathways
that lead to VEGF production in activated muscle. For example,
Hoier and colleagues reported that the contraction-induced
increase in VEGF mRNA and protein in humans were dependent
on adenosine [22]. Also, angiogenic responses to exercise training
were abolished in PGC-1a, ERRa [21] and p38c knockout mice
[65], with all animals having reduced VEGF expression. These
studies and the results of our work presented here indicate that
further work is required to further characterize the complexities of
VEGF production in muscle in order to fully comprehend what
signals regulate VEGF production downstream of the overload
stimulus. Our data also emphasize the importance of specifically
evaluating myocyte-derived VEGF as opposed to VEGF from
other sources, such as endothelial cells. It is interesting to note, in
previous work where VEGF was selectively deleted in endothelial
cells, significant impairments in vascular integrity and function
were found, but no measurable alterations in vascular density were
noted [66]. In contrast, loss of myocyte-specific VEGF has resulted
in significant losses of muscle capillarity, but without evidence of
impaired vascular integrity [12,34]. This is consistent with the
current finding that overload stimulated angiogenesis is abolished
in muscle VEGF deficient mice (Figure 1A, B), but more
importantly would suggest that the actions of VEGF may be
context and site dependent.
In summary, we have shown that Ang II signaling contributes to
the basal production of VEGF by muscle cells and provides
evidence that Ang II-dependent production of matrix-associated
forms of VEGF is involved in the communication between muscle
cells and endothelial cells. Our study also revealed that myocyte-
derived VEGF is critical for new capillary growth following muscle
overload. However, blockade of AT1R signaling does not reduce
muscle overload-induced VEGF production and capillary growth.
Together, these findings emphasize the absolute requirement for
muscle-derived VEGF in the promotion of capillary growth within
muscle, and indicate that the expression of this critical factor
within active muscle is protected through functional redundancy of
multiple signal pathways.
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